Mayne Pharma Group Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mayne Pharma Group Limited
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."
- Contract Research, Toxicology Testing-CRO
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Diagnostic Imaging Equipment & Supplies
Laboratory Testing Services
- Anatomical Pathology
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Halcygen Pharmaceuticals
- Mayne Pharma International
- Mayne Pharma Ventures Pty Ltd